Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Unknown 3Recruiting 3Not yet recruiting 3Active not recruiting 3Terminated 2Completed 2Withdrawn 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 35HER2-positive Breast Cancer 3Brain Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Motor Activity 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Invasive Breast Cancer 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1

Interventions

pertuzumab 3Trastuzumab 3Paclitaxel 2Docetaxel 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1atezolizumab 1Carboplatin 1Ado-Trastuzumab Emtansine 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Breast Cancer × pertuzumab × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡